University Lecturer; Honorary Consultant Urological Surgeon
As lead for Surgical Oncology within the Department of Surgery, Mr Stewart aims to leverage the strengths of academic surgical oncology (clinical surgery, trials and biosampling/translational research) to enhance the cure rate following surgical treatment of cancer. As a University Lecturer in Urological Surgery, Grant has a specific interest in optimising management of patients with initially localised renal cancer, an area of great need within the disease.
Clinically, Mr Stewart undertakes a full range of treatments for renal cancer at Addenbrooke’s Hospital, from robotic partial nephrectomy for small renal cancers to multi-speciality surgery for locally advanced disease. In order to make practice changing developments in this area Mr Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical excellence in managing renal cancer at Addenbrooke’s Hospital, Cambridge. To deliver on the above goals, Grant coordinates the Cambridge Renal Cancer Collaboration (CamRenCan) a group of over 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cancer research. His research is focussed on the key clinical questions in initially localised RCC, namely: early detection/screening, early diagnosis approaches, optimal follow-up strategies, neoadjuvant and adjuvant therapies.
Mr Stewart’s current research metrics are: over £39 million research grant/clinical trial income and over 120 peer reviewed publications.
Mr Stewart moved to Cambridge in October 2015 from a post as Senior Lecturer in Urological Surgery at the University of Edinburgh where he led the Edinburgh Urological Cancer Group. Grant developed and still co-directs the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), a Scotland-wide kidney cancer biorepository of 1200 patients with high quality clinical data linkage.
Mr Stewart chairs the Renal Cancer Surgical Subgroup of the National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group, is Co-Chair of the Renal Cross Channel Group, sits on the Medical Advisory Board for Cambridge Medical Robotics, is Chair of the Scientific and Education Committee of The Urology Foundation, is a member of the Clinical Expert Review Panel of Cancer Research UK and is CI/PI for several renal cancer clinical trials. Grant is Programme Director of the University of Edinburgh, Urology ChM.
M.D. Young, T.J. Mitchell, F.A. Vieira Braga, M.G.B. Tran, B.J. Stewart, J. Ferdinand, G. Collord, R.A. Botting, D-M. Popescu, K.W. Loudon, R. Vento-Tormo, E. Stephenson, A. Cagan, S. Farndon, M. Del Castillo Velasco-Herrera, C. Guzzo, N. Richoz, L. Mamanova, T. Aho, J.N. Armitage, A.C.P. Riddick, I. Mushtaq, S. Farrell, D. Rampling, J. Nicholson, A. Filby, J. Burge, S. Lisgo, P.H. Maxwell, S. Lindsay, A.Y. Warren, G.D. Stewart, N. Sebire, N. Coleman, M. Haniffa, S. Teichmann, M. Clatworthy, S. Behjati. Single cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018; 361: 594–599.
P. Rodrigues, S.A. Patel, L. Harewood, I. Olan, E. Vojtasova, S.E. Syafruddin, M.N. Zaini, E.K. Richardson, J. Burge, A.Y. Warren, G.D. Stewart, K. Saeb-Parsy, S.A. Samarajiwa, S. Vanharanta. NF-kappaB-dependent lymphoid enhancer co-option promotes renal carcinoma metastasis. Cancer Discovery. 2018. 8:850-865.
T.J. Mitchell, S. Turajlic, A. Rowan, D. Nicol, J.H.R. Farmery, T. O’Brien, I. Martincorena, P. Tarpey, N. Angelopoulos, L.R. Yates, A.P. Butler, K. Raine, G.D. Stewart, B. Challacombe, A. Fernando, J. I. Lopez, S. Hazell, A. Chandra, S. Chowdhury, S. Rudman, A. Soultati, G. Stamp, N. Fotiadis, L. Pickering, L. Au, L. Spain, J. Lynch, M. Stares, J. Teague, F. Maura, D.C. Wedge, S. Horswell, T. Chambers, K. Litchfield, H. Xu, A. Stewart, R. Elaidi, S. Oudard, N. McGranahan, I. Csabai, M. Gore, P.A. Futreal, J. Larkin, A.G. Lynch, Z. Szallasi, C. Swanton, P.J. Campbell, on behalf of the Renal TRACERx consortium. Timing the landmark events in the evolution of clear cell renal cell carcinoma: TRACERx Renal. Cell. 2018; 173(3): 611-623.
A.L.R. Lubbock, G.D. Stewart (joint 1st author), F.C. O’Mahony, A. Laird, P. Mullen, M. O’Donnell, T. Powles, D.J. Harrison, I.M. Overton. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine. 2017. 15(1):118.
S.H. Rossi, R. Hsu, C. Blick, V. Goh, P. Nathan, D. Nicol, S. Fleming, M. Sweeting, E.C.F. Wilson, G.D. Stewart. A meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals. British Journal of Surgery. 2017; 104: 648–659.
G.D. Stewart, F.C. O’Mahony, A. Laird, L. Eory, A.L.R. Lubbock, A. Mackay, J. Nanda, M. O’Donnell, P. Mullen, S.A. McNeill, A.C.P. Riddick, D. Berney, A. Bex, M. Aitchison, I.M. Overton, D.J. Harrison, T. Powles. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clinical Cancer Research. 2015; 21(18): 4212–23.
G.D. Stewart, F.C. O’Mahony, A. Laird, S. Rashid, S.A. Martin, L. Eory, A.L.R. Lubbock, J. Nanda, M. O’Donnell, A. Mackay, P. Mullen, S.A. McNeill, A.C.P. Riddick, M. Aitchison, D. Berney, A. Bex, I.M. Overton, D.J. Harrison, T. Powles. Carbonic anhydrase 9 expression increases with VEGF targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. European Urology. 2014; 66: 956-963.
K. Sharpe, G.D. Stewart (joint 1st author), A. Mackay, C. Van Neste, C. Rofe, D.M. Berney, I. Kayani, A. Bex, E. Wan, F. O’Mahony, M. O’Donnell, S. Chowdhury, R. Doshi, C. Ho Yen, M. Gerlinger, D. Baker, N.R. Smith, B.R. Davies, A. Sahdev, E. Boleti, T. de Meyer, W. Van Criekinge, L. Beltran, Y-J. Lu, D. Harrison, A.R. Reynolds, T. Powles. The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clinical Cancer Research. 2013; 19: 6924-6934.
Areas of expertise
kidney cancer, renal cell cancer, translational research, biomarker development, clinical trials, window-of-opportunity trials, neoadjuvant trials, adjuvant trials, screening, device trials.